Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.

Yang XY, Yin S, Yu YF, Hu G, Hang FZ, Zhou ML, Liu P, Jian WX

European review for medical and pharmacological sciences1 Aug 2023Cited by 2 (Europe PMC)

PMID37606127DOI10.26355/eurrev_202308_33290PepBankPUB-37606127

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of trials in type 2 diabetes, tirzepatide 15 mg reduced HbA1c more than placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with placebo, the meta-analysis demonstrated that tirzepatide 15 mg reduced hemoglobin-type-A1C (HbA1c) (p<0.00001), fasting-serum-glucose (FSG) (p<0.00001), and weight (p<0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612701
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of trials in type 2 diabetes, tirzepatide 15 mg reduced fasting serum glucose more than placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered fasting blood glucose more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseFasting serum glucose vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with placebo, the meta-analysis demonstrated that tirzepatide 15 mg reduced hemoglobin-type-A1C (HbA1c) (p<0.00001), fasting-serum-glucose (FSG) (p<0.00001), and weight (p<0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612702
03HumanSystematic reviewEfficacy outcome
In a meta-analysis of trials in type 2 diabetes, tirzepatide 15 mg reduced body weight more than placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg reduced body weight more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseWeight vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with placebo, the meta-analysis demonstrated that tirzepatide 15 mg reduced hemoglobin-type-A1C (HbA1c) (p<0.00001), fasting-serum-glucose (FSG) (p<0.00001), and weight (p<0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612703
04HumanSystematic reviewEfficacy outcome
In a meta-analysis of trials in type 2 diabetes, tirzepatide 15 mg reduced HbA1c more than insulin.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than insulin.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c vs insulin
Study
n: not reported in source
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with insulin, tirzepatide 15 mg reduced HbA1c (p<0.00001), FSG (p<0.00007), and weight (p<0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612704
05HumanSystematic reviewEfficacy outcome
In a meta-analysis of trials in type 2 diabetes, tirzepatide 15 mg reduced fasting serum glucose more than insulin.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered fasting blood glucose more than insulin.
Peptide
Tirzepatide
Outcome
DecreaseFasting serum glucose vs insulin
Study
n: not reported in source
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with insulin, tirzepatide 15 mg reduced HbA1c (p<0.00001), FSG (p<0.00007), and weight (p<0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612705
06HumanSystematic reviewEfficacy outcome
In a meta-analysis of trials in type 2 diabetes, tirzepatide 15 mg reduced body weight more than insulin.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg reduced body weight more than insulin.
Peptide
Tirzepatide
Outcome
DecreaseWeight vs insulin
Study
n: not reported in source
Comparator
Insulin
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with insulin, tirzepatide 15 mg reduced HbA1c (p<0.00001), FSG (p<0.00007), and weight (p<0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612706
07HumanSystematic reviewEfficacy outcome
In a meta-analysis of trials in type 2 diabetes, tirzepatide 15 mg reduced HbA1c more than GLP-1 receptor agonists.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than GLP-1 receptor agonists.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c vs GLP-1 RA
Study
n: not reported in source
Comparator
GLP-1 receptor agonist
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with glucagon-like-peptide-1 receptor-agonist (GLP-1 RA), tirzepatide 15 mg reduced HbA1c (p=0.00004), FSG (p=0.001), and weight (p<0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612707
08HumanSystematic reviewEfficacy outcome
In a meta-analysis of trials in type 2 diabetes, tirzepatide 15 mg reduced fasting serum glucose more than GLP-1 receptor agonists.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered fasting blood glucose more than GLP-1 receptor agonists.
Peptide
Tirzepatide
Outcome
DecreaseFasting serum glucose vs GLP-1 RA
Study
n: not reported in source
Comparator
GLP-1 receptor agonist
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with glucagon-like-peptide-1 receptor-agonist (GLP-1 RA), tirzepatide 15 mg reduced HbA1c (p=0.00004), FSG (p=0.001), and weight (p<0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612708
09HumanSystematic reviewEfficacy outcome
In a meta-analysis of trials in type 2 diabetes, tirzepatide 15 mg reduced body weight more than GLP-1 receptor agonists.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg reduced body weight more than GLP-1 receptor agonists.
Peptide
Tirzepatide
Outcome
DecreaseWeight vs GLP-1 RA
Study
n: not reported in source
Comparator
GLP-1 receptor agonist
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with glucagon-like-peptide-1 receptor-agonist (GLP-1 RA), tirzepatide 15 mg reduced HbA1c (p=0.00004), FSG (p=0.001), and weight (p<0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612709
10HumanSystematic reviewSafety outcome
In a meta-analysis of trials in type 2 diabetes, total adverse events were higher with tirzepatide 15 mg than with placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg caused more adverse events overall than placebo.
Peptide
Tirzepatide
Outcome
IncreaseTotal adverse events vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
The total AEs (p=0.02) and gastrointestinal (GI) AEs (p=0.03) were higher in tirzepatide 15 mg than in the placebo, while hypoglycemia (<54 mg/dl) was comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612710
11HumanSystematic reviewSafety outcome
In a meta-analysis of trials in type 2 diabetes, gastrointestinal adverse events were higher with tirzepatide 15 mg than with placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg caused more stomach and gut side effects than placebo.
Peptide
Tirzepatide
Outcome
IncreaseGastrointestinal adverse events vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
The total AEs (p=0.02) and gastrointestinal (GI) AEs (p=0.03) were higher in tirzepatide 15 mg than in the placebo, while hypoglycemia (<54 mg/dl) was comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612711
12HumanSystematic reviewSafety outcome
In a meta-analysis of trials in type 2 diabetes, hypoglycemia (<54 mg/dl) was comparable between tirzepatide 15 mg and placebo.
In plain wordsIn adults with type 2 diabetes, low blood sugar (below 54 mg/dl) was about as common with tirzepatide 15 mg as with placebo.
Peptide
Tirzepatide
Outcome
No significant changeHypoglycemia (<54 mg/dl) vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
The total AEs (p=0.02) and gastrointestinal (GI) AEs (p=0.03) were higher in tirzepatide 15 mg than in the placebo, while hypoglycemia (<54 mg/dl) was comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612712
13HumanSystematic reviewSafety outcome
In a meta-analysis of trials in type 2 diabetes, major adverse cardiovascular events-4 were lower with tirzepatide 15 mg than with insulin.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg was linked to fewer major cardiovascular events than insulin.
Peptide
Tirzepatide
Outcome
DecreaseMACE-4 vs insulin
Study
n: not reported in source
Comparator
Insulin
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
The major adverse cardiovascular events-4 (MACE-4) (p=0.03) and hypoglycemia (<54 mg/dl) (p<0.00001) of tirzepatide 15 mg were lower when compared to insulin, while total AEs (p=0.03) were increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612713
14HumanSystematic reviewSafety outcome
In a meta-analysis of trials in type 2 diabetes, hypoglycemia (<54 mg/dl) was lower with tirzepatide 15 mg than with insulin.
In plain wordsIn adults with type 2 diabetes, low blood sugar (below 54 mg/dl) was less common with tirzepatide 15 mg than with insulin.
Peptide
Tirzepatide
Outcome
DecreaseHypoglycemia (<54 mg/dl) vs insulin
Study
n: not reported in source
Comparator
Insulin
Outcome group
Adverse events · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
The major adverse cardiovascular events-4 (MACE-4) (p=0.03) and hypoglycemia (<54 mg/dl) (p<0.00001) of tirzepatide 15 mg were lower when compared to insulin, while total AEs (p=0.03) were increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612714
15HumanSystematic reviewSafety outcome
In a meta-analysis of trials in type 2 diabetes, total adverse events were increased with tirzepatide 15 mg compared with insulin.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg caused more adverse events overall than insulin.
Peptide
Tirzepatide
Outcome
IncreaseTotal adverse events vs insulin
Study
n: not reported in source
Comparator
Insulin
Outcome group
Adverse events · Whole body
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
The major adverse cardiovascular events-4 (MACE-4) (p=0.03) and hypoglycemia (<54 mg/dl) (p<0.00001) of tirzepatide 15 mg were lower when compared to insulin, while total AEs (p=0.03) were increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612715
16HumanSystematic reviewSafety outcome
In a meta-analysis of trials in type 2 diabetes, total adverse events were comparable between tirzepatide 15 mg and GLP-1 receptor agonists.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg caused about as many adverse events overall as GLP-1 receptor agonists.
Peptide
Tirzepatide
Outcome
No significant changeTotal adverse events vs GLP-1 RA
Study
n: not reported in source
Comparator
GLP-1 receptor agonist
Outcome group
Adverse events · Whole body
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with GLP-1 RA, tirzepatide 15 mg was comparable in safety endpoints in total AEs and GI AEs, while hypoglycemia (<54 mg/dl) (p=0.04) was higher.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612716
17HumanSystematic reviewSafety outcome
In a meta-analysis of trials in type 2 diabetes, gastrointestinal adverse events were comparable between tirzepatide 15 mg and GLP-1 receptor agonists.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg caused about as many gut side effects as GLP-1 receptor agonists.
Peptide
Tirzepatide
Outcome
No significant changeGastrointestinal adverse events vs GLP-1 RA
Study
n: not reported in source
Comparator
GLP-1 receptor agonist
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with GLP-1 RA, tirzepatide 15 mg was comparable in safety endpoints in total AEs and GI AEs, while hypoglycemia (<54 mg/dl) (p=0.04) was higher.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612717
18HumanSystematic reviewSafety outcome
In a meta-analysis of trials in type 2 diabetes, hypoglycemia (<54 mg/dl) was higher with tirzepatide 15 mg than with GLP-1 receptor agonists.
In plain wordsIn adults with type 2 diabetes, low blood sugar (below 54 mg/dl) was more common with tirzepatide 15 mg than with GLP-1 receptor agonists.
Peptide
Tirzepatide
Outcome
IncreaseHypoglycemia (<54 mg/dl) vs GLP-1 RA
Study
n: not reported in source
Comparator
GLP-1 receptor agonist
Outcome group
Adverse events · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Compared with GLP-1 RA, tirzepatide 15 mg was comparable in safety endpoints in total AEs and GI AEs, while hypoglycemia (<54 mg/dl) (p=0.04) was higher.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight databases were searched for clinical trials on tirzepatide for type 2 diabetes with a time limit of November 2022.
Report a problemFND-3760612718

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.